Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

110 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells.
Overwijk WW, Theoret MR, Finkelstein SE, Surman DR, de Jong LA, Vyth-Dreese FA, Dellemijn TA, Antony PA, Spiess PJ, Palmer DC, Heimann DM, Klebanoff CA, Yu Z, Hwang LN, Feigenbaum L, Kruisbeek AM, Rosenberg SA, Restifo NP. Overwijk WW, et al. Among authors: theoret mr. J Exp Med. 2003 Aug 18;198(4):569-80. doi: 10.1084/jem.20030590. J Exp Med. 2003. PMID: 12925674 Free PMC article.
Clinical and immunologic impact of short-course enzalutamide alone and with immunotherapy in non-metastatic castration sensitive prostate cancer.
Madan RA, Karzai F, Donahue RN, Al-Harthy M, Bilusic M, Rosner II, Singh H, Arlen PM, Theoret MR, Marté JL, Cordes L, Couvillon A, Hankin A, Williams M, Owens H, Lochrin SE, Chau CH, Steinberg S, Figg WD, Dahut W, Schlom J, Gulley JL. Madan RA, et al. Among authors: theoret mr. J Immunother Cancer. 2021 Mar;9(3):e001556. doi: 10.1136/jitc-2020-001556. J Immunother Cancer. 2021. PMID: 33664086 Free PMC article. Clinical Trial.
Vaccine-stimulated, adoptively transferred CD8+ T cells traffic indiscriminately and ubiquitously while mediating specific tumor destruction.
Palmer DC, Balasubramaniam S, Hanada K, Wrzesinski C, Yu Z, Farid S, Theoret MR, Hwang LN, Klebanoff CA, Gattinoni L, Goldstein AL, Yang JC, Restifo NP. Palmer DC, et al. Among authors: theoret mr. J Immunol. 2004 Dec 15;173(12):7209-16. doi: 10.4049/jimmunol.173.12.7209. J Immunol. 2004. PMID: 15585842 Free PMC article.
Assumptions of the tumor 'escape' hypothesis.
Restifo NP, Antony PA, Finkelstein SE, Leitner WW, Surman DP, Theoret MR, Touloukian CE. Restifo NP, et al. Among authors: theoret mr. Semin Cancer Biol. 2002 Feb;12(1):81-6. doi: 10.1006/scbi.2001.0399. Semin Cancer Biol. 2002. PMID: 11926416 Free PMC article. Review.
Immunological and antitumor effects of IL-23 as a cancer vaccine adjuvant.
Overwijk WW, de Visser KE, Tirion FH, de Jong LA, Pols TW, van der Velden YU, van den Boorn JG, Keller AM, Buurman WA, Theoret MR, Blom B, Restifo NP, Kruisbeek AM, Kastelein RA, Haanen JB. Overwijk WW, et al. Among authors: theoret mr. J Immunol. 2006 May 1;176(9):5213-22. doi: 10.4049/jimmunol.176.9.5213. J Immunol. 2006. PMID: 16621986 Free PMC article.
110 results